Next generation vascular shunt

About us About us About us

Our Mission

Firm aims to introduce to the market a new generation coronary shunt for use during coronary artery bypass grafting surgery (CABG).

CorFlow technology is being developed with several technological innovations increasing safety for the patients and facilitating shunt use by cardiac surgeons. Next generation coronary shunt is dedicated to improve the results of coronary artery bypass grafting and expand global number of less invasive CABG technique - beating heart, off-pump coronary artery bypass grafting (OPCAB).

Shunts in cardiac surgery

Coronary artery bypass grafting is the most common cardiac surgical procedure performed in the world. It is performed in patients with coronary artery stenosis - ischemic heart disease (IHD). The number of people with IHD is growing every year in the global population. Main factors stimulating this growth are: acceleration of human population increase, aging of developed countries populations and improvement of access to modern cardiac surgical care in developing countries.

Coronary shunt

Coronary shunt is a tube inserted into the coronary artery at the site of anastomosis. Shunts seal the anastomosis site and provide visibility for the surgeon while applying sutures. Shunts eliminate the need of coronary artery occlusion during the procedure. They ensure the flow through the artery during anastomosis. At the last stage of performing the anastomosis, the shunt is removed from the artery and the suture is tied. Shunts are primarily dedicated to CABG surgery performed on the beating heart (OPCAB).

Classic method of CABG

The classic method of CABG surgery is carried out using extracorporeal circulation with cardiac arrest. Such procedure requires the use of heart-lung machine (cardiopulmonary bypass, CPB). The less invasive technique is performed without CPB - on a beating heart. Resignation from extracorporeal circulation in some groups of patients results in lower risk of bleeding and blood transfusion, stroke, renal failure, cognitive disorders, cardiac arrhythmia and sometimes even lower mortality. However, this technique is more technically demanding.

Project

The theoretical assumptions for the technology were created in order to eliminate the disadvantages of shunts currently used in operating rooms around the world. Through the time-line of the project all of them will be materialized in prototypes and checked for proof-of-concept.

Phase 1

In the first stage of the project all technology concepts will be subjected to computer modelling, including fluid dynamics. The designs that work best in digital conditions will be printed and checked in real environment. Ex-vivo studies will be carried out for next selection of the solutions.

Phase 2

Agreed by the team Proof-of-Concept covers achievement full functionality and safety on animal beating heart model.

Phase 3

Second phase of the project is a certification and production. In final phase CorFlow shunt will be introduced to global markets.

News

Phase 1 launched

At the beginning of 2023, the first phase of the project was launched. Currently, two groups of engineers and scientists are working on the design of the CorFlow shunt structure and CFD modeling. A model of coronary arteries was developed, rheological conditions and hemodynamic conditions of the CorFlow working environment were mapped. Further technical solutions are being verified. 

Growing market for CorFlow

Data on 140k patients showed that off-pump coronary artery bypass grafting (OPCAB) has significant advantages over on-pump method in older population. Off-pump versus on-pump coronary artery bypass grafting for octogenarians: a meta-analysis involving 146 372 patients. This is how projection becomes fact. The number of older patients is increasing thus CorFlow is being invented to support OPCAB technique.

Clin Cardiol2022 Apr;45(4):331-341.

Our team

Firm is conducted by physicians, including cardiac surgeon, specialists in medical devices designing, engineers, specialist of computational fluid dynamic modeling and managers experienced in med-tech sector and technology transfer to global markets.

Przemysław Furdal
Przemysław Furdal

Management Board, Founder and Chief Executive Officer

Przemysław Furdal is experienced manager of research and development projects in medical devices sector: CEO of the Heart Sense, CEO of Heart Guard and vice-president and co-founder of Quantum Innovations. Participant of over 30 complex projects. 

Certified patent attorney experienced in creating and realizing full strategy for medical devices intellectual property protection. 

Moreover, master degree in medical chemistry (graduated on University of Gdańsk), organic chemistry (graduated on University of Warsaw) and management (graduated on Warsaw School of Economics). 

Grzegorz Suwalski MD, PhD
Grzegorz Suwalski MD, PhD

Management Board, Founder and Vice-President

Dr Suwalski is an active specialist in cardiac surgery. Author of over 120 scientific publications and congress reports. Co-author of the implementations of several innovative surgical techniques published in medical journals and press (including The New York Times). He holds doctorate on mathematical analysis of electrocardiographic signal in prediction of heart rhythm disturbances after cardiac surgery.

A member several international scientific societies. Trained in centres in Poland, Switzerland, Netherlands and Germany. Lecturer at the Medical University of Warsaw. He graduated at First Faculty of Medicine at the Medical University of Warsaw and has a PhD in medical sciences awarded by the Military Institute of Medicine in Warsaw.

Co-creator of several medical devices: Heart Guard technology, Heart Sense biosensor. Experienced in management of research and development projects in medical devices sector: Chief Technology Officer at Heart Sense, Chief Technology Officer at Heart Guard, Founder and CEO of Quantum Innovations.

Andrzej Morawiec MD
Andrzej Morawiec MD

Supervisory Board

Physician, entrepreneur, investor and manager in medical company. Specialized in nephrology and working for years as consultant in Germany. Founder and creator of private dialysis therapy centers in Germany. Experienced in commercialization in medical sector. Former board member of B-Braun – global medical company, present in cardiac surgical devices market.

Pawlos Mandzios
Pawlos Mandzios

Supervisory Board

Pawlos Mandzios is an active entrepreneur with 15 years of experience in development of numerous business ventures. Graduated in several universities: Medical University of Wroclaw, Wroclaw University of Economics and Sorbonne Université where he completed specialized studies in Management at MBA level.

For many years he has been involved in new technologies and HR industry. He has successfully participated in the development of start-ups which are active in the market till now. He is co-founder of start-up companies established at GK Work Service S.A. where he worked as manager and member of the Management Board. 

Pavlos Mandzios has been managing more than 50 business projects funded by EU with capitalization level exceeding 150 mln PLN. Currently he develops startup companies as co-founder and leads acceleration of newly established entities. Since 2016 he is also an investor and originator of new projects in the field of new technologies and IT. Currently he develops following projects: ChallyU and Unfold (awarded by the National Center for Research and Development as rising star in the GameINN Sector Program).

Krzysztof Dudziński, PhD
Krzysztof Dudziński, PhD

Patent attorney

Krzysztof Dudziński is a patent attorney and a partner in a law firm SDP Sierżant Dudziński. He is a lecturer at University of Warsaw (Faculty of Chemistry) where he teaches The Art of Patenting.

He specializes in developing a strategy of intellectual property protection in the fields of pharma, chemistry and new technologies, including med-tech. He conducts patent searches and handles patent prosecution & invalidation proceedings. He is also involved in patent litigation where he masterminds technical argumentation for clients. 

He has strong scientific credentials, confirmed by a PhD degree in chemistry supported by experience in lab & clinical trials. He adopts a business-oriented approach which is valued by clients.

Klikając Zgoda akceptujesz zapisywanie wszystkich danych cookie na twoim urządzeniu. Kliknięcie Odmowa oznacza zapisywanie tylko danych niezbędnych do funkcjonowania strony. Więcej informacji o cookie w polityce prywatności.
ustawienia
Odmowa
Zgadzam się
×

Niezbędne pliki cookies

Te pliki cookie są niezbędne do działania strony i nie można ich wyłączyć. Służą na przykład do utrzymania zawartości koszyka użytkownika. Możesz ustawić przeglądarkę tak, aby blokowała te pliki cookie, ale wtedy strona nie będzie działała poprawnie.

Zawsze aktywne

Analityczne pliki cookie

Te pliki cookie pozwalają liczyć wizyty i źródła ruchu. Dzięki tym plikom wiadomo, które strony są bardziej popularne i w jaki sposób poruszają się odwiedzający stronę. Wszystkie informacje gromadzone przez te pliki cookie są anonimowe.